Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 19/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899256 | 1.00 | KCNA3 (0.78) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3897148 | 1.00 | KCNA3 (0.78) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3896875 | 0.90 | MEN1 (0.78) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3900687 | 0.90 | MEN1 (0.78) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3895509 | 0.90 | MEN1 (0.78) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3896266 | 0.90 | MEN1 (0.78) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3893648 | 0.89 | KCNA3 (0.82) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3893644 | 0.89 | KCNA3 (0.82) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL13067120 | 0.89 | KCNA3 (0.62) | KCNA3MEN1ALDH1A1KMT2A | |
| SCHEMBL3899408 | 0.88 | KCNA3 (1.00) | KCNA3MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143965-B1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-6632836-B1 | To treat autoimmune disorders, cardiac arrhythmias and the like | MERCK & CO., INC. | 2003-10-14 | — | — | US | disclosed |
| EP-1143965-A4 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1143965-A1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000025770-A1 | CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | KCNA3 18/4885MEN1 4430/4885ALDH1A1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.